Regulation of thrombin-induced plasminogen activator inhibitor-1 in 4T1 murine breast cancer cells

Blood Coagulation and Fibrinolysis

Volumn 22, Issue 7, 2011, Pages 576-582

  McEachron, Troy A ^a,c   Church, Frank C ^a,b   MacKman, Nigel ^a,b  

^a Department of Pathology and Laboratory Medicine ^*  (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

plasminogen activator inhibitor 1; protease activated receptor 1; protease activated receptor 2; signaling; thrombin

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEIN P42; PROTEIN P44; THROMBIN;

ANIMAL CELL; ARTICLE; BREAST CANCER; ENZYME ACTIVATION; ENZYME INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; ANIMALS; BREAST NEOPLASMS; EARLY GROWTH RESPONSE PROTEIN 1; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PLASMINOGEN ACTIVATOR INHIBITOR 1; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, PAR-1; RECEPTOR, PAR-2; SIGNAL TRANSDUCTION; THROMBIN; TUMOR CELLS, CULTURED;

EID: 80053615530     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3283497647     Document Type: Article

References (40)

1. Coughlin SR. Protease-activated receptors start a family. Proc Natl Acad Sci USA 1994; 91:9200-9202. (Pubitemid 24297881)
2. O'Brien PJ, Molino M, Kahn M, Brass LF. Protease activated receptors: theme and variations. Oncogene 2001; 20:1570-1581. (Pubitemid 32336845)
3. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64:1057-1068. (Pubitemid 121001193)
4. Bhattacharjee G, Ahamed J, Pawlinski R, Liu C, Mackman N, Ruf W, et al. Factor Xa binding to annexin 2 mediates signal transduction via protease-activated receptor 1. Circ Res 2008; 102:457-464. (Pubitemid 351651111)
5. Mize GJ, Wang W, Takayama TK. Prostate-specific kallikreins-2 and-4 enhance the proliferation of DU-145 prostate cancer cells through protease-activated receptors-1 and-2. Mol Cancer Res 2008; 6:1043-1051.
6. Gratio V, Beaufort N, Seiz L, Maier J, Virca GD, Debela M, et al. Kallikreinrelated peptidase 4: a new activator of the aberrantly expressed proteaseactivated receptor 1 in colon cancer cells. Am J Pathol 2010; 176:1452-1461.
7. LudemanMJ, Kataoka H, Srinivasan Y,Esmon NL, Esmon CT, Coughlin SR. PAR1 cleavage and signaling in response to activated protein C and thrombin. J Biol Chem 2005; 280:13122-13128.
8. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002; 296:1880-1882. (Pubitemid 34596276)
9. Kuliopulos A, Covic L, Seeley SK, Sheridan PJ, Helin J, Costello CE. Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy. Biochemistry 1999; 38:4572-4585.
10. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005; 120:303-313. (Pubitemid 40222426)
11. Camerer E, Huang W, Coughlin SR. Tissue factor-and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci USA 2000; 97:5255-5260. (Pubitemid 30313705)
12. Ramsay AJ, Dong Y, Hunt ML, Linn M, Samaratunga H, Clements JA, et al. Kallikrein-related peptidase 4 (KLK4) initiates intracellular signaling via protease-activated receptors (PARs). KLK4 and PAR-2 are co-expressed during prostate cancer progression. J Biol Chem 2008; 283:12293-12304.
13. Al-Ani B, Saifeddine M, Kawabata A, Hollenberg MD. Proteinase activated receptor 2: role of extracellular loop 2 for ligand-mediated activation. Br J Pharmacol 1999; 128:1105-1113. (Pubitemid 29512045)
14. Molino M, Barnathan ES, Numerof R, Clark J, Dreyer M, Cumashi A, et al. Interactions of mast cell tryptase with thrombin receptors and PAR-2. J Biol Chem 1997; 272:4043-4049. (Pubitemid 27078466)
15. O'Brien PJ, Prevost N, Molino M, Hollinger MK, Woolkalis MJ, Woulfe DS, et al. Thrombin responses in human endothelial cells. Contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombin-cleaved PAR1. J Biol Chem 2000; 275:13502-13509. (Pubitemid 30257415)
16. McEachron TA, Pawlinski R, Richards KL, Church FC, Mackman N. Protease-activated receptors mediate crosstalk between coagulation and fibrinolysis. Blood 2010; 116:5037-5044.
17. Tantivejkul K, Loberg RD, Mawocha SC, Day LL, John LS, Pienta BA, et al. PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. J Cell Biochem 2005; 96:641-652. (Pubitemid 41504661)
18. Albrektsen T, Sørensen BB, Hjortø GM, Fleckner J, Rao LVM, Petersen LC. Transcriptional program induced by factor VIIa-tissue factor, PAR1 and PAR2 in MDA-MB-231 cells. J Thromb Haemost 2007; 5:1588-1597. (Pubitemid 47091396)
19. Gramling MW, Church FC. Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment. Thromb Res 2010; 125:377-381.
20. Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 2009; 7:4-13.
21. BinderBR,MihalyJ,PragerGW.uPAR-uPA-PAI-1interactionsandsignaling: a vascular biologist's view. Thromb Haemost 2007; 97:336-342.
22. Maillard CM, Bouquet C, Petitjean MM, Mestdagt M, Frau E, Jost M, et al. Reduction of brain metastases in plasminogen activator inhibitor-1-deficient mice with transgenic ocular tumors. Carcinogenesis 2008; 29:2236-2242.
23. Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, Castellino FJ. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res 2000; 60:5839-5847.
24. Nagamine Y. Transcriptional regulation of the plasminogen activator inhibitor type 1: with an emphasis on negative regulation. Thromb Haemost 2008; 100:1007-1013.
25. Wyrzykowska P, Stalińska K, Wawro M, Kochan J, Kasza A. Epidermal growth factor regulates PAI-1 expression via activation of the transcription factor Elk-1. Biochim Biophys Acta 2010; 1799:616-621.
26. Boccaccio C, Sabatino G, Medico E, Girolami F, Follenzi A, Reato G, et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 2005; 434:396-400. (Pubitemid 40469184)
27. Jung S, Song HS, Park S, Chung S, Kim Y. Pyruvate promotes tumor angiogenesis through HIF-1-dependent PAI-1 expression. Int J Oncol 2011; 38:571-576. http://www.ncbi.nlm.nih.gov/pubmed/21132271. [Accessed 3 December 2010].
28. Konrad L, Scheiber JA, Schwarz L, Schrader AJ, Hofmann R. TGF-beta1 and TGF-beta2 strongly enhance the secretion of plasminogen activator inhibitor-1 and matrix metalloproteinase-9 of the human prostate cancer cell line PC-3. Regul Pept 2009; 155:28-32.
29. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3:1101-1108. (Pubitemid 351818697)
30. Li Q, Yang S, Maeda Y, Sladek FM, Sharrocks AD, Martins-Green M. MAP kinase phosphorylation-dependent activation of Elk-1 leads to activation of the co-activator p300. EMBO J 2003; 22:281-291. (Pubitemid 36119434)
31. Lim CP, Jain N, Cao X. Stress-induced immediate-early gene, egr-1, involves activation of p38/JNK1. Oncogene 1998; 16:2915-2926. (Pubitemid 28383276)
32. Liao H, Hyman MC, Lawrence DA, Pinsky DJ. Molecular regulation of the PAI-1 gene by hypoxia: contributions of Egr-1, HIF-1alpha, and C/EBPalpha. FASEB J 2007; 21:935-949. (Pubitemid 46348266)
33. Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: an update. Biochem J 2003; 371:199-204. (Pubitemid 36458094)
34. Sharrocks AD. Complexities in ETS-domain transcription factor function and regulation: lessons from the TCF (ternary complex factor) subfamily. The Colworth Medal Lecture. Biochem Soc Trans 2002; 30:1-9.
35. Altieri DC. Molecular cloning of effector cell protease receptor-1, a novel cell surface receptor for the protease factor Xa. J Biol Chem 1994; 269:3139-3142. (Pubitemid 24237619)
36. Yao X, Liu F, Li J, Qi X, Wu B, Yin H, et al. Significance of effector protease receptor-1 expression and its relationship with proliferation and apoptotic index in patients with primary advanced gastric adenocarcinoma. World J Gastroenterol 2004; 10:1262-1267. (Pubitemid 39162428)
37. Silverman ES, Collins T. Pathways of Egr-1-mediated gene transcription in vascular biology. Am J Pathol 1999; 154:665-670. (Pubitemid 29122584)
38. Suen JY, Gardiner B, Grimmond S, Fairlie DP. Profiling gene expression induced by protease-activated receptor 2 (PAR2) activation in human kidney cells. PLoS One 2010; 5:e13809.
39. Camerer E, Rottingen JA, Gjernes E, Larsen K, Skartlien AH, Iversen JG, et al. Coagulation factors VIIa and Xa induce cell signaling leading to up-regulation of the egr-1 gene. J Biol Chem 1999; 274:32225-32233.
40. Liao H, Hyman MC, Lawrence DA, Pinsky DJ. Molecular regulation of the PAI-1 gene by hypoxia: contributions of Egr-1, HIF-1alpha, and C/EBPalpha. FASEB J 2007; 21:935-949. (Pubitemid 46348266)